Chemical genetic approaches to kinase drug discovery

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 5, 2005, Pages 638-645

  Gallion, Steven L ^a   Qian, Dapeng ^a  

^a CGI Pharmaceuticals Inc   (United States)

Author keywords

ASKA; Chemical genetics; Drug discovery; Kinase; Selectivity

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CANERTINIB; DORAMAPIMOD; ERLOTINIB; GEFITINIB; GW 400426; IMATINIB; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; ROSCOVITINE; SORAFENIB; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; CHEMICAL GENETICS; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GENETIC ENGINEERING; REVIEW;

ANIMALS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; PHOSPHOTRANSFERASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 24044440105     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science (2002) 298(5600):1912-1934.
2. Cohen P: Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov (2002) 1(4):309-315.
3. Kumar S, Boehm J, Lee JC: p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov (2003) 2(9):717-726.
4. ter Haar E, Walters WP, Pazhanisamy S, Taslimi P, Pierce AC, Bemis GW, Salituro FG, Harbeson SL: Kinase chemogenomics: Targeting the human kinome for target validation and drug discovery. Mini Rev Med Chem (2004) 4(3):235-253.
5. Klebl BM: Chemical kinomics - a target gene family approach in chemical biology. Drug Disc Today: Technol (2004) 1(1):25-34.
6. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 111(9):1287-1295.
7. Adams J, Huang P, Patrick D: A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis. Curr Opin Chem Biol (2002) 6(4):486-492.
8. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J (2000) 351(Pt 1):95-105.
9. Bain J, McLauchlan H, Elliott M, Cohen P: The specificities of protein kinase inhibitors: An update. Biochem J (2003) 371(Pt 1):199-204.
10. Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM et al: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol (2005) 23(3):329-336. Presents details of a study in which a set of clinically relevant compounds was broadly profiled against a set of 119 protein kinases using phage display. Many previously unknown interactions were identified and it was demonstrated that off-target activities were widely distributed.
11. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB: Potent and selective inhibitors of the Abl kinase: Phenylamino-pyrimidine (PAP) derivatives. Bioorg Med Chem Lett (1997) 7(2):187-192.
12. Noble ME, Endicott JA, Johnson LN: Protein kinase inhibitors: insights into drug design from structure. Science (2004) 303(5665):1800-1805.
13. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ, Gao X, Hendle J, Keegan K, Leon BC, Muller-Dieckmann HJ et al: A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem (2004) 279(53):55827-55832.
14. Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, Stein-Geriach M, Missio A, Gotten M, Muller S, Daub H: Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Mol Cell Proteomics (2004) 3(12):1181-1193. Discusses the use of affinity chromatography to identify p38 MAPK and RIPK2 as new targets in previously undiscovered therapeutic areas.
15. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Geriach M, Missio A, Gotten M, Daub H: An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA (2003) 100(26):15434-15439.
16. Aronov AM, Murcko MA: Toward a pharmacophore for kinase frequent hitters. J Med Chem (2004) 47(23):5616-5619. Discusses a pharmacophore consisting of five features, which can explain the indiscriminate binding of inhibitors to kinases.
17. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerte H: Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta (2004) 1697(1-2):243-257. Describes a study using structure-activity data in the context of residues known to have significant contacts with inhibitors to construct a dendrogram of kinases. The resulting selectivity dendrogram differed significantly from the corresponding phylogenic tree.
18. Kauvar LM, Higgins DL, Villar HO, Sportsman JR, Engqvist-Goldstein A, Bukar R, Bauer KE, Dilley H, Rocke DM: Predicting ligand binding to proteins by affinity fingerprinting. Chem Biol (1995) 2(2):107-118.
19. Frye SV: Structure-activity relationship homology (SARAH): A conceptual framework for drug discovery in the genomic era. Chem Biol (1999) 6(1):R3-R7.
20. Kunkel EJ, Plavec I, Nguyen D, Melrose J, Rosler ES, Kao LT, Wang Y, Hytopoulos E, Bishop AC, Bateman R, Shokat KM et al: Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev Technol (2004) 2(4):431-441.
21. Clark MP, Laughlin SK, Laufersweiler MJ, Bookland RG, Brugel TA, Golebiowski A, Sabat MP, Townes JA, VanRens JC, Djung JF, Natchus MG et al: Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-α production. J Med Chem (2004) 47(11):2724-2727.
22. Shokat K, Velleca M: Novel chemical genetic approaches to the discovery of signal transduction inhibitors. Drug Disc Today (2002) 7(16):872-879.
23. Zhang C, Kenski DM, Paulson JL, Bonshtien A, Sessa G, Cross JV, Templeton DJ, Shokat KM: A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nat Methods (2005)2(6):435-441.
24. Qian D, Srinivasa S, Mitchell S, Elkin L, Eustice D, Barbosa J, Whitney A, Pippin D, Darrow D, Di Paolo J, Chaudhuri S et al: Discovery and development of multiplex angiogenesis inhibitors that target EphB4: Validation with a novel chemical-genetics based in vivo model. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland (2004). Provides the first report of the generation of ASKA knockin mice that are fully functional and can be specifically inhibited by an ASKA inhibitor in vivo.
25. Benton BK, Rommel C, Velleca M, Pasquali C: Mining for protein kinase substrates: Integration of biochemistry, genetics and prateomics. Curr Proteomics (2004) 1(2):83-102.
26. Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON: Sole Bcr-Abl inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci USA (2004) 101(50):17456-17461. Describes the use of Bcr-Abl ASKA to demonstrate that Bcr-Abl is the primary target and c-Kit is the secondary target for MPD, and that both targets must be inhibited for effective treatment of the disease.
27. Heck S, Qian X, Velleca M: Genetically engineered mouse models for drug discovery: New chemical genetic approaches. Curr Drug Disc Technol (2004) 1(1):13-26.
28. Wang H, Shimizu E, Tang YP, Cho M, Kyin M, Zuo W, Robinson DA, Alaimo PJ, Zhang C, Morimoto H, Zhuo M et al: Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc Natl Acad Sci USA (2003) 100(7):4287-4292.
29. Chen X, Ye H, Kuruvilla R, Ramanan N, Scangos KW, Zhang C, Johnson NM, England PM, Shokat KM, Ginty DD: A chemical-genetic approach to studying neurotrophin signaling. Neuron (2005) 46(1):13-21. Discusses the generation of TrkA, TrkB and TrkC ASKA knockin mice with complete functionality and inhibitability.
30. Fan QW, Zhang C, Shokat KM, Weiss WA: Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Curr Biol (2002) 12(16):1386-1394.
31. Fan QW, Specht KM, Zhang C, Goldenberg DD, Shokat KM, Weiss WA: Combinatorial efficacy achieved through two-point blockade within a signaling pathway - a chemical genetic approach. Cancer Res (2003) 63(24):8930-8938.
32. Whitney JA: Reference systems for kinase drug discovery: Chemical genetic approaches to cell-based assays. Assay Drug Dev Technol (2004) 2(4):417-429.
33. Kung C, Kenski DM, Dickerson SH, Howson RW, Kuyper LF, Madhani HD, Shokat KM: Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor. Proc Natl Acad Sci USA (2005) 102(10):3587-3592. Describes the use of a combination of ASKA and microarray technologies to establish signatures of transcriptional changes for comparative analysis. This study identified a second target in yeast for the Cdk1 inhibitor GW-400426.
34. Jiang S, DiPaolo J, Alderucci S, Peppers J, Qian X, Qian D, Awad T, Velleca M, Whitney A: Chemical genetic transcriptional fingerprinting for selectivity profiling of Btk inhibitors. Nat Chem Biol(2005): manuscript submitted. Describes the use of a combination of ASKA and microarray technologies to establish a signature of transcriptional changes for specific Btk inhibition, facilitating selectivity profiling for Btk inhibitors during lead optimization.